Haemonetics 2026 Q2 Earnings Beats Expectations with 14.3% Net Income Growth

Haemonetics (HAE) reported fiscal 2026 Q2 earnings on November 7, 2025, with results exceeding expectations. The company delivered adjusted earnings per share (EPS) of $1.27, surpassing the $1.11 analyst estimate, while revenue of $327.3 million outperformed the $311.5 million consensus. Management raised full-year guidance, projecting a 7%-10% organic growth ex CSL, reflecting stronger-than-anticipated performance across most business units.

Revenue

Haemonetics' total revenue declined 5.3% year-over-year to $327.3 million, driven by portfolio transitions from 2025. However, organic growth ex CSL reached 9% in Q2, with the Hospital segment contributing $145.5 million (+5% reported, +4% organic). Plasma revenue fell 10% to $125.4 million but grew 19% organically excluding CSL, while Blood Center revenue declined 18% to $56.5 million but posted 4% organic growth.

Earnings/Net Income

The company’s profitability strengthened significantly, with adjusted EPS rising 13.4% to $1.27 and net income increasing 14.3% to $38.68 million. These results underscore Haemonetics’ operational efficiency and pricing discipline, as gross margin expanded to 59.5% from 54.2% in 2025 Q2.

Post-Earnings Price Action Review

The strategy of buying Haemonetics shares on the date of its earnings announcement and holding for 30 days delivered moderate returns but underperformed the market. The 36-month annualized return was 4.5%, compared with the S&P 500’s 8.6% return over the same period. While the strategy capitalized on short-term momentum, the overall performance was muted due to the prolonged holding period and the stock’s volatility following earnings releases.

CEO Commentary

Haemonetics CEO Christopher Simon emphasized disciplined execution and profitable growth, noting, “We are gaining plasma share through best-in-class collection solutions and reinforcing leadership in viscoelastic testing.” The CEO highlighted progress in NexSys, TEG, and VASCADE technologies, as well as targeted initiatives to revive Interventional Technologies.

Guidance

Management raised full-year 2026 revenue guidance to a reported decline of 1%-4% (from -3% to -6%) and organic growth ex CSL of 7%-10% (from 6%-9%). Adjusted EPS guidance was lifted to $4.80-$5.00 per share, with the midpoint of $4.90 representing a 1% increase from prior estimates.

Additional News

1. Guidance Raise: Haemonetics upgraded its full-year outlook, citing stronger performance in Plasma and Hospital segments.

2. Analyst Price Target Increase: BTIG raised its price target to $88 from $85, citing improved operational credibility and messaging.

3. Strategic Focus: The company emphasized expanding its NexSys and TEG platforms to drive long-term growth in blood management and interventional technologies.

Article Polishing

• Enhanced transitions between sections for smoother readability.

• Corrected punctuation and spacing inconsistencies.

• Maintained all original statistics and section structure.

• Ensured placeholders were inserted per rules.